FDA approves AstraZeneca’s baxdrostat for select hypertension patients

AstraZeneca announced that the U.S. Food and Drug Administration has granted approval for its blood‑pressure pill baxdrostat, targeting a specific group of patients with hypertension.

The approval is highlighted as a key component of the company's strategy to reach $80 billion in annual revenue by 2030, underscoring its growing portfolio in cardiovascular medicines.

Analysts note that while the drug adds to AstraZeneca’s pipeline, competitors are expected to introduce alternative treatments in the near future, which could influence market dynamics.